Literature DB >> 23925991

Alterations of motor cortical excitability and anatomy in Unverricht-Lundborg disease.

Nils Danner1, Petro Julkunen, Jelena Hyppönen, Eini Niskanen, Laura Säisänen, Mervi Könönen, Päivi Koskenkorva, Ritva Vanninen, Reetta Kälviäinen, Esa Mervaala.   

Abstract

Unverricht-Lundborg disease is the most common form of progressive myoclonus epilepsies. In addition to generalized seizures, it is characterized by myoclonus, which usually is the most disabling feature of the disease. Classically, the myoclonus has been attributed to increased excitability of the primary motor cortex. However, inhibitory cortical phenomena have also been described along with anatomical alterations. We aimed to characterize the relationship between the excitability and anatomy of the motor cortex and their association with the severity of the clinical symptoms. Seventy genetically verified patients were compared with forty healthy controls. The symptoms were evaluated with the Unified Myoclonus Rating Scale. Navigated transcranial magnetic stimulation was applied to characterize the excitability of the primary motor cortex by determining the motor thresholds and cortical silent periods. In addition, the induced cortical electric fields were estimated using individual scalp-to-cortex distances measured from MRIs. A cortical thickness analysis was performed to elucidate possible disease-related anatomical alterations. The motor thresholds, cortical electric fields, and silent periods were significantly increased in the patients (P < 0.01). The silent periods correlated with the myoclonus scores (r = 0.48 to r = 0.49, P < 0.001). The scalp-to-cortex distance increased significantly with disease duration (r = 0.56, P < 0.001) and correlated inversely with cortical thickness. The results may reflect the refractory nature of the myoclonus and indicate a possible reactive cortical inhibitory mechanism to the underlying disease process. This is the largest clinical series on Unverricht-Lundborg disease and the first study describing parallel pathophysiological and structural alterations associated with the severity of the symptoms.
© 2013 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  EPM1; Unverricht-Lundborg disease; progressive myoclonus epilepsy; transcranial magnetic stimulation motor cortex

Mesh:

Substances:

Year:  2013        PMID: 23925991     DOI: 10.1002/mds.25615

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

1.  Progressive volume loss and white matter degeneration in cstb-deficient mice: a diffusion tensor and longitudinal volumetry MRI study.

Authors:  Otto Manninen; Teemu Laitinen; Kimmo K Lehtimäki; Saara Tegelberg; Anna-Elina Lehesjoki; Olli Gröhn; Outi Kopra
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

2.  The network sustaining action myoclonus: a MEG-EMG study in patients with EPM1.

Authors:  Silvana Franceschetti; Laura Canafoglia; Fabio Rotondi; Elisa Visani; Alice Granvillano; Ferruccio Panzica
Journal:  BMC Neurol       Date:  2016-11-07       Impact factor: 2.474

3.  Impaired osteoclast homeostasis in the cystatin B-deficient mouse model of progressive myoclonus epilepsy.

Authors:  Otto Manninen; Tero Puolakkainen; Jemina Lehto; Elina Harittu; Aki Kallonen; Marko Peura; Tiina Laitala-Leinonen; Outi Kopra; Riku Kiviranta; Anna-Elina Lehesjoki
Journal:  Bone Rep       Date:  2015-11-06

4.  Cystatin B is essential for proliferation and interneuron migration in individuals with EPM1 epilepsy.

Authors:  Francesco Di Matteo; Fabrizia Pipicelli; Christina Kyrousi; Isabella Tovecci; Eduardo Penna; Marianna Crispino; Angela Chambery; Rosita Russo; Ane Cristina Ayo-Martin; Martina Giordano; Anke Hoffmann; Emilio Ciusani; Laura Canafoglia; Magdalena Götz; Rossella Di Giaimo; Silvia Cappello
Journal:  EMBO Mol Med       Date:  2020-05-07       Impact factor: 12.137

Review 5.  Transcranial magnetic stimulation as a tool to understand genetic conditions associated with epilepsy.

Authors:  Katri Silvennoinen; Simona Balestrini; John C Rothwell; Sanjay M Sisodiya
Journal:  Epilepsia       Date:  2020-08-12       Impact factor: 6.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.